Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
Would you offer RT to a patient who had a RP showing pT3b pN1 Gleason 9 prostate cancer with elevated post-op PSA?
Would it matter if their PET axumin was negative?
Answer from: Radiation Oncologist at Academic Institution
If Axumin PET is negative for metastatic sites (prostatic Bed or Pelvic Nodes are excluded) Or even totally negative, I would treat.
Sign In
or
Register
to read more
Answer from: Radiation Oncologist at Community Practice
I would favor pet scan if meets threshold based on psa and plan treatment accordingly
Sign In
or
Register
to read more
6190
6181
Related Questions
How do you counsel/advise patients when asked to compare ultrahypofractionated radiotherapy with the TULSA procedure?
What are your top takeaways in GU Cancers from ESMO 2025?
How would you treat a patient with isolated CNS relapse of seminoma?
In what situations would you utilize radiation therapy for management of high grade urothelial carcinoma of the prostate?
What are your institution's standard liquid intake instructions for prostate cancer patients going through definitive external beam radiation?
Would you offer re-irradiation for a prostate local recurrence after I-125 seed implant >10 years ago in a healthy young patient with life expectancy >15 years?
How do you interpret isolated PSMA-avid sites in a patient with prostate cancer with no pelvic or RP LN uptake?
How would you approach radiation for node-positive prostate cancer in a patient with an aortic and/or common iliac arterial aneurysm not meeting criteria for surgical repair?
How would you manage a patient who developed an intraprostatic abscess after SpaceOAR injection, prior to starting radiation?
Do you recommend placement of a rectal spacer when delivering radiotherapy to the prostate in patients with oligometastatic prostate cancer?